Vaccination against Herpes zoster in patients with immune-mediated inflammatory rheumatic diseases: new data

Abstract

Patients with immune-mediated inflammatory rheumatic diseases (IIRD) are more likely to develop herpes zoster (HZ) than individuals in the general population. Live attenuated vaccines and inactivated recombinant vaccines with adjuvant are available to prevent the disease and its complications. Live attenuated vaccine can be used in patients with IIRD if certain conditions are met, although these cannot always be fulfilled. The advantage of the inactivated recombinant adjuvant vaccine is that it can be used against a background of anti-rheumatic therapy. The review analyzes foreign studies on the safety, immunogenicity and efficacy of recombinant adjuvant vaccine against HZ in patients with IIRD.

Keywords

• immune-inflammatory rheumatic diseases
• rheumatoid arthritis
• systemic lupus erythematosus
• glucocorticoids
• janus kinase inhibitors
• biologic disease-modifying antirheumatic drugs
• herpes zoster
• vaccination
• recombinant adjuvant vaccine